Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients With Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Confirmed diagnosis of VHL disease
- One or more measurable CNS hemangioblastoma, if symptomatic, must be refractory or not amenable to standard therapy, if asymptomatic, must have had at least one prior neurosurgical treatment/ procedure; and/or: at least one untreatable or treatment-refractory retinal hemangioblastoma that is causing impaired visual function
- Karnofsky Performance Status >=60
- Life expectancy > 3 months
- Able to sign informed consent
- Adequate hematologic status, liver and kidney function
Exclusion criteria:
- Patients with other VHL-related tumors requiring or amenable to standard treatment
- Severe or uncontrolled concurrent illnesses that could compromise participation in the study
- Total urinary protein in 24 hour collection > 500 mg
- Pregnant or breast feeding females, adults of reproductive potential not using effective contraception (hormonal methods not considered effective due to possible decreased effectiveness secondary to drug interaction with PTK787). Women of childbearing potential must have negative serum pregnancy test prior to initiation of treatment.
- Acute or chronic liver disease
- Diagnosis of HIV infection
- GI function that may alter absorption of PTK787
- Patients taking coumadin (warfarin sodium)
- Prior therapies (investigational drugs, chemotherapy) within 4 weeks prior to study entry
- Prior therapies (biologic, hormonal, immunotherapy, radiation therapy, surgery) within two weeks prior to study entry.
- Patients unwilling or unable to comply with protocol requirements
- Patients with concurrent, non VHL-related malignancies other than non-melanoma skin cancer
- Patients with contraindication to MRI imaging
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PTK787/ZK 222584
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Evaluate efficacy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Evaluate changes in dynamic contrast enhanced magnetic resonance imaging
|
|
To explore the correlation of the pharmacokinetics
|
|
To assess changes in surrogate markers of angiogenesis
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Hemangioma
- Neoplasms, Vascular Tissue
- Abnormalities, Multiple
- Neurocutaneous Syndromes
- Ciliopathies
- Angiomatosis
- Hemangioma, Capillary
- Von Hippel-Lindau Disease
- Hemangioblastoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Vatalanib
Other Study ID Numbers
Other Study ID Numbers
- CPTK787 0144
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.